IRADIMED CORPORATION (IRMD)

Every figure this model derived for IRMD, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 2,020,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 59,080,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 86,722,000 AssetsCurrent 2026-06-30
current liabilities 9,164,000 LiabilitiesCurrent 2026-06-30
equity 101,748,000 StockholdersEquity 2026-06-30
ocf 27,138,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 86,338,963 Revenues 2026-06-30
sbc 2,853,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up IRMD on one particular measure came for.

RatioValue
cash operating margin37.11
current ratio15.23
current ratio reported9.46
deferred revenue growth6.49
dilution pct0.55
ebit cagr17.61
ebit yoy15.73
fcf margin29.09
growth cv0.35
operating margin31.92
owner earnings margin25.79
revenue growth11.21
revenue growth per share10.61
roic51.02
rule of 4043.13
sbc pct revenue3.3

What to be careful about

What this model itself distrusts about IRMD's figures. Written by the derivation as it ran, not added afterwards.